NEW YORK, May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Sage and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On April 17, 2024, Sage iss ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Ashley Kaplowitz - Vice President-Investor Relations & Capital Markets Barry Greene - Chief Executive Officer & Member-Board of Directors Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - JPMorgan Ritu Baral - TD Cowen Laura Chico - Wedbush Securiti ...

First Quarter 2024 Financial Results April 25, 2024 Safe Harbor Statement and cost of clinical trials or development efforts and ourability to proceed with further development. • The slides presentedtodayand the accompanying oral presentations contain forward-lookingstatements, – Even if our other product candidates are successfully developed and approved, the number ofpatients with which may be identifi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 27-4486580 (State or other juri ...

Exhibit 99.1 Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Achieved $6.2 million in ZURZUVAE™ (zuranolone) collaboration revenue during the first quarter of 2024, representing 50% of the net revenues reported by Biogen Encouraging initial demand for ZURZUVAE; More than 700 prescriptions shipped and delivered in the first quarter of 2024 Payor coverage now in place for a majority of commercially covered lives for ZURZUVAE in the treatment of wo ...

SAGE Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Conference Call February 14, 2024 8:00 AM ET Company Participants Barry Greene - President, CEO & Director Kimi Iguchi - CFO & Treasurer Laura Gault - Chief Medical Officer Chris Benecchi - Chief Business Officer Ashley Kaplowitz - Director, IR Conference Call Participants Matt Leskowitz - Goldman Sachs Anupam Rama - J.P. Morgan Ritu Baral - TD Cowen James Condulis - Stifel Tazeen Ahmad - Bank of America Brian Abraham - RBC Capital Markets Poorna Kannan ...

Fourth Quarter and Full Year 2023 Financial Results February 14, 2024 Safe Harbor Statement ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 27-4486580 (State or Other Jurisdictio ...

SAGE Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Conference Call November 7, 2022 8:00 AM ET Company Participants Ashley Kaplowitz - Director, IR Barry Greene - President, CEO & Director Christopher Benecchi - Chief Business Officer Kimi Iguchi - CFO & Treasurer Laura Gault - Chief Medical Officer Conference Call Participants Ritu Baral - TD Cowen Anupam Rama - JPMorgan Chase & Co. Tazeen Ahmad - Bank of America Merrill Lynch Salveen Richter - Goldman Sachs Group Jay Olson - Oppenheimer Ami Fadia - Ne ...

Third Quarter 2023 Financial Results November 7, 2023 Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity", "goal", "mission", "potential," "target", or "continue," and other similar expressions. • Forward-looking statements in this presentation ...